Clinical trials: B ALL
Hepatitis B
Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B
This study evaluates the safety and immunogenicity of FP-02.2, a new therapeutic Hepatitis B vaccine, administered as an add-on therapy to entecavir or tenofovir.
- Trial name
- NCT02496897
- Testing
- FP-02.2 Vaccine, IC31® Adjuvant
- Where
- 21 sites in South Korea, United Kingdom
- Volunteers
- 61 people
- Sponsor
- Altimmune, Inc.
Multiple Myeloma, Solid Tumors
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
The purpose of this trial is to characterize the safety and toxicity of DKN-01 by determining a maximum-tolerated dose and associated dose limiting toxicity. To evaluate the pharmacodynamic response in patients with cancer.
- Conditions
- Multiple Myeloma, Solid Tumors, Non-Small Cell Lung Cancer
- Trial name
- NCT01457417
- Testing
- DKN-01
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Leap Therapeutics, Inc.
Hemophilia B
Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B
The primary objective of the study was to evaluate the safety of recombinant coagulation factor IX Fc fusion protein (rFIXFc, BIIB029) in previously untreated patients (PUPs) with severe hemophilia B.
- Trial name
- PUPs B-LONG (NCT02234310)
- Testing
- rFIXFc
- Where
- 27 sites in United States, Australia and 9 more
- Volunteers
- 33 people
- Sponsor
- Bioverativ, a Sanofi company
Chronic Lymphocytic Leukemia
Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease
The goal of this clinical research study is to learn if Revlimid (lenalidomide) can help to reduce the level of leukemia in your body. The safety of this drug will also be studied.
- Trial name
- NCT00632359
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00513747
- Testing
- rituximab, fludarabine phosphate
- Where
- 387 sites in United States, Canada
- Volunteers
- 84 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Richter's Transformation
PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)
This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, single-arm, 2-stage, open-label phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety…
- Trial name
- NCT02378038
- Testing
- PNT2258
- Where
- 9 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
The purpose of this study is to evaluate the effects, good and bad of a new drug called ixazomib (also called MLN9708), when it is given along with a common treatment combination, called Dose-Adjusted EPOCH-R (DA-EPOCH-R, for…
- Conditions
- Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, MYC Gene Mutation
- Trial name
- NCT02481310
- Testing
- Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- Northwestern University
Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia
Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia
This phase II trial studies how well dasatinib works in treating patients with chronic lymphocytic leukemia (CLL). Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia
- Trial name
- NCT01441882
- Testing
- Dasatinib, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- OHSU Knight Cancer Institute
Chronic Lymphocytic Leukemia
Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders
The goal of this clinical research study is to learn if giving CAMPATH-1H with rituximab can shrink or slow the growth of the disease in patients with chronic lymphoid disorders that have either not responded or whose disease has…
- Trial name
- NCT00071396
- Testing
- Campath-1H, Rituximab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
B-Cell Lymphoma Originating in the CNS
The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma
The primary purpose of the study will be testing the dosing of temozolomide to find the target dose that a person can tolerate. The other part of the study will be determining how helpful it can be to CNS lymphoma patients by…
- Trial name
- DRBEAT (NCT01235793)
- Testing
- Temozolomide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cedars-Sinai Medical Center
Chronic Lymphocytic Leukemia
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
This is a global, Phase IIIb, multicenter, open-label, single-arm study to evaluate the safety and efficacy of acalabrutinib 100 mg twice daily (bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL).
- Trial name
- ASSURE (NCT04008706)
- Testing
- Acalabrutinib
- Where
- 108 sites in United States, Australia and 15 more
- Volunteers
- 552 people
- Sponsor
- AstraZeneca
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer
RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00134017
- Testing
- Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
This phase II study is designed to determine the clinical efficacy of PD-1 blockade, using the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475), administered as consolidation therapy after autologous stem cell transplant…
- Conditions
- Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma
- Trial name
- NCT02362997
- Testing
- Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 82 people
- Sponsor
- Dana-Farber Cancer Institute
HIV-1 Infection
Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women
The primary objective of this study is to evaluate the efficacy of switching to a fixed-dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing on a regimen consisting of…
- Trial name
- NCT02652624
- Testing
- E/C/F/TAF, E/C/F/TDF, ATV
- Where
- 56 sites in United States, Dominican Republic and 4 more
- Volunteers
- 472 people
- Sponsor
- Gilead Sciences
Kidney, Polycystic
HALT Progression of Polycystic Kidney Disease Study B
The efficacy of interruption of the renin-angiotensin-aldosterone system (RAAS) on the progression of cystic disease and on the decline in renal function in autosomal dominant kidney disease (ADPKD) will be assessed in two…
- Trial name
- HALT PKD B (NCT01885559)
- Testing
- Lisinopril, Telmisartan
- Where
- 7 sites in United States
- Volunteers
- 486 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis B
Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant
The objective of this 96-week study was to evaluate the safety and antiviral efficacy of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF, coformulated; Truvada®) with or without hepatitis B immunoglobulin (HBIg) in…
- Trial name
- NCT00507689
- Testing
- FTC/TDF, Hepatitis B Immunoglobulin (HBIg)
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Gilead Sciences
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
The main purpose of this study is to see if the combination of ofatumumab with high dose methylprednisolone followed by additional treatment with ofatumumab and lenalidomide can help people with relapsed or refractory CLL/SLL get…
- Trial name
- NCT01497496
- Testing
- High Dose Methylprednisolone (HDMP), Ofatumumab, Lenalidomide
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Meningococcal Disease, Meningococcal Meningitis
Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine
This study compares the safety and immunogenicity profile of combined hepatitis A/B vaccine given alone or concomitantly with MenACWY-CRM to healthy adults.
- Conditions
- Meningococcal Disease, Meningococcal Meningitis, Hepatitis A, Hepatitis B
- Trial name
- NCT01453348
- Testing
- MenACWY-CRM, Combined inactivated hepatitis A & recombinant hepatitis B, Recombinant hepatitis B vaccine
- Where
- 4 sites in Germany
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Hypertension, Diabetes
Biomarker Guided Therapies in Stage A/B Heart Failure
Despite advances in cardiovascular care, the occurrence of heart failure (HF) is steadily increasing. The increase in HF rates poses enormous challenges, as once an individual becomes symptomatic or requires hospitalization with…
- Conditions
- Hypertension, Diabetes, Cardiovascular Disease
- Trial name
- NCT02230891
- Testing
- Carvedilol, Spironolactone, Usual care
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- VA Office of Research and Development
Chronic Lymphocytic Leukemia
Campath Maintenance in Chronic Lymphocytic Leukemia
This is a study designed to test whether giving campath (also known as alemtuzumab) on a maintenance schedule will prolong the time until the patient requires chemotherapy.
- Trial name
- NCT00587847
- Testing
- Campath
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwell Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.